Pasithea Therapeutics (KTTA) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 40.8% versus a loss of 97.3%. Over five years, KTTA leads with a -99.2% price change compared with -99.8% for TVRD. Pasithea Therapeutics is the larger company by market cap ($15.6 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | TVRD |
|---|---|---|
| Share price | $0.4675 | $1.03 |
| Market cap | $15.62M | $13.74M |
| 1-day change | +6.03% | -4.63% |
| YTD return | -63.76% | -74.88% |
| 1-year return | -40.82% | -97.29% |
| 5-year return | -99.22% | -99.77% |
| EPS (TTM) | $-1.59 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $43.65 |
| 52-week low | $0.281 | $0.93 |
| Distance from 52-week high | -77.31% | -97.64% |
| Analyst consensus | none | buy |
| Avg. price target upside | +541.71% | +798.06% |
| Average volume | 225.69K | 424.45K |
| Shares outstanding | 33.41M | 13.34M |
| Employees | 5 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed TVRD by 56.5 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
KTTA vs TVRD FAQ
Which is bigger, Pasithea Therapeutics or Tvardi Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.62M compared with $13.74M for Tvardi Therapeutics (TVRD).
Which stock has performed better over the past year, KTTA or TVRD?
KTTA returned -40.82% over the past 12 months, compared with -97.29% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.